Fulltext

Long-Term Antibiotic Treatment for Crohn's Disease: Systematic Review and Meta-Analysis of Placebo-Controlled Trials

Feller, Martin ; Huwiler, Karin ; Schoepfer, Alain ; Shang, Aijing ; Furrer, Hansjakob ; Egger, Matthias

In: Clinical Infectious Diseases, 2010, vol. 50, no. 4, p. 473-480

Aggiungi alla tua lista
    Titre
    • Long-Term Antibiotic Treatment for Crohn's Disease: Systematic Review and Meta-Analysis of Placebo-Controlled Trials
    Auteur
    • Feller, Martin. Institute of Social and Preventive Medicine, Bern, Switzerland
    • Huwiler, Karin. Institute of Social and Preventive Medicine, Bern, Switzerland
    • Schoepfer, Alain. Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, Bern, Switzerland
    • Shang, Aijing. Institute of Social and Preventive Medicine, Bern, Switzerland
    • Furrer, Hansjakob. Institute of Infectious Diseases, University of Bern, Bern, Switzerland
    • Egger, Matthias. Institute of Social and Preventive Medicine, Bern, Switzerland
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • Clinical Infectious Diseases, 2010, vol. 50, no. 4, p. 473-480. The University of Chicago Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:290878
    Summary
    Background. We investigated the effectiveness of long-term antibiotic treatment in patients with Crohn's disease. Methods. We performed a systematic review and meta-analysis of randomized clinical trials. Data sources were Medline (from 1966 through June 2009), EMBASE (from 1980 through June 2009), Cochrane Central Register of Controlled Trials (issue 3, 2009), and references from relevant publications. Trials that compared antibiotic therapy during at least 3 months with placebo were included. Outcomes were remission in patients with active disease and relapse in patients with inactive disease. Results from intention-to-treat analyses were combined in a random-effects meta-analysis, stratified by class of drug. Odds ratios (ORs) >1 indicate superiority of antibacterial treatment over placebo. Numbers needed to treat for 1 year to keep 1 additional patient in remission were calculated. Results. Sixteen trials that examined 13 treatment regimens in 865 patients were included in the meta-analysis. The median duration of treatment was 6 months (range, 3-24 months). Three trials of nitroimidazoles showed benefit, with a combined OR of 3.54 (95% confidence interval [CI], 1.94-6.47). Similarly, the combined OR from 4 trials of clofazimine was 2.86 (95% CI, 1.67-4.88). For patients with active disease, the number needed to treat was 3.4 (95% CI, 2.3-7.0) for nitroimidazoles and 4.2 (95% CI, 2.7-9.3) for clofazimine. The corresponding numbers needed to treat for inactive disease were 6.1 (95% CI, 5.0-9.7) and 6.9 (95% CI, 5.4-12.0). No benefit was evident for classic drugs against tuberculosis (3 trials; OR, 0.58; 95% CI, 0.29-1.18). Results for clarithromycin were heterogeneous (I2=77%; P=.005) and not combined in the meta-analysis. Conclusions. Long-term treatment with nitroimidazoles or clofazimine appears to be effective in patients with Crohn's disease